Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).

Wu J, Wang A, Li X, Chen C, Qi Z, Hu C, Wang W, Wu H, Huang T, Zhao M, Wang W, Hu Z, Liu Q, Wang B, Wang L, Li L, Ge J, Ren T, Xia R, Liu J, Liu Q.

Cancer Biol Ther. 2019 Mar 20:1-9. doi: 10.1080/15384047.2019.1579958. [Epub ahead of print]

PMID:
30894066
2.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).

Liu F, Wang B, Wang Q, Qi Z, Chen C, Kong LL, Chen JY, Liu X, Wang A, Hu C, Wang W, Wang H, Wu F, Ruan Y, Qi S, Liu J, Zou F, Hu Z, Wang W, Wang L, Zhang S, Yun CH, Zhai Z, Liu J, Liu Q.

Oncotarget. 2016 Jul 19;7(29):45562-45574. doi: 10.18632/oncotarget.10037.

3.

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.

Liu X, Wang B, Chen C, Jiang Z, Hu C, Wu H, Zhang Y, Liu X, Wang W, Wang J, Hu Z, Wang A, Huang T, Liu Q, Wang W, Wang L, Wang W, Ren T, Li L, Xia R, Ge J, Liu Q, Liu J.

Eur J Med Chem. 2018 Dec 5;160:61-81. doi: 10.1016/j.ejmech.2018.10.007. Epub 2018 Oct 5.

PMID:
30317026
4.

[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].

Jiang Q, Qin Y, Lai Y, Jiang H, Shi H.

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):7-13. doi: 10.3760/cma.j.issn.0253-2727.2016.01.002. Chinese.

PMID:
26876246
5.

Characterization of cancer stem cells in chronic myeloid leukaemia.

Jørgensen HG, Holyoake TL.

Biochem Soc Trans. 2007 Nov;35(Pt 5):1347-51. Review.

PMID:
17956348
6.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.

Ben-Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus JL, Rankin S, Clark RE, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf TH, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason GV, Holyoake TL, Loges S.

Clin Cancer Res. 2017 May 1;23(9):2289-2300. doi: 10.1158/1078-0432.CCR-16-1930. Epub 2016 Nov 17.

7.

MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.

Yeh YY, Liou JP, Lee YL, Lin JY, Huang HM.

Invest New Drugs. 2017 Aug;35(4):427-435. doi: 10.1007/s10637-017-0457-9. Epub 2017 Mar 27.

PMID:
28349229
8.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
9.

Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.

O'Hare T, Pollock R, Stoffregen EP, Keats JA, Abdullah OM, Moseson EM, Rivera VM, Tang H, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Shakespeare WC, Dalgarno D, Clackson T, Sawyer TK, Deininger MW, Druker BJ.

Blood. 2004 Oct 15;104(8):2532-9. Epub 2004 Jul 15.

10.

HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.

Yun SM, Jung KH, Kim SJ, Fang Z, Son MK, Yan HH, Lee H, Kim J, Shin S, Hong S, Hong SS.

Cancer Lett. 2014 Jun 28;348(1-2):50-60. doi: 10.1016/j.canlet.2014.03.012. Epub 2014 Mar 18.

PMID:
24657654
11.

SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.

Wang D, Zheng Y, Li J, Wu H, Li X, Tang Y, Liu Y, Li J, Sun R, Zhou Y, Sun J, Yang Y.

Eur J Pharmacol. 2017 Sep 15;811:117-124. doi: 10.1016/j.ejphar.2017.06.001. Epub 2017 Jun 6.

PMID:
28595903
12.

Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM.

Cancer. 2011 May 1;117(9):1800-11. doi: 10.1002/cncr.25717. Epub 2010 Nov 29. Review. Erratum in: Cancer. 2011 Aug;117(15):3535.

13.

Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.

Zeng X, Zhao H, Li Y, Fan J, Sun Y, Wang S, Wang Z, Song P, Ju D.

Autophagy. 2015;11(2):355-72. doi: 10.4161/15548627.2014.994368.

14.

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.

Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.

Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3.

15.

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.

Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA.

Tumour Biol. 2016 Sep;37(9):12643-12654. Epub 2016 Jul 21.

16.

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C.

Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9.

17.

Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Halbach S, Hu Z, Gretzmeier C, Ellermann J, Wöhrle FU, Dengjel J, Brummer T.

Cell Commun Signal. 2016 Feb 24;14:6. doi: 10.1186/s12964-016-0129-y.

18.

The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.

Ru Y, Wang Q, Liu X, Zhang M, Zhong D, Ye M, Li Y, Han H, Yao L, Li X.

Sci Rep. 2016 Jun 22;6:28352. doi: 10.1038/srep28352.

19.

Targeted drugs in chronic myeloid leukemia.

Gora-Tybor J, Robak T.

Curr Med Chem. 2008;15(29):3036-51. Review.

PMID:
19075651
20.

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

Iqbal Z, Aleem A, Iqbal M, Naqvi MI, Gill A, Taj AS, Qayyum A, ur-Rehman N, Khalid AM, Shah IH, Khalid M, Haq R, Khan M, Baig SM, Jamil A, Abbas MN, Absar M, Mahmood A, Rasool M, Akhtar T.

PLoS One. 2013;8(2):e55717. doi: 10.1371/journal.pone.0055717. Epub 2013 Feb 8.

Supplemental Content

Support Center